For primary hypogonadism, testosterone replacement therapy may be appropriate since the problem is in the testes, and external testosterone may help restore normal levels. However, for secondary hypogonadism, TRT is not ideal because it does not address the underlying problems with the hypothalamus or pituitary, leading to testicular atrophy and infertility, and creating a long-term dependence on external testosterone.
Instead, medications called selective estrogen receptor modulators (SERMs) such as clomiphene citrate and enclomiphene citrate that stimulate the natural hormone production process are preferred in secondary hypogonadism, as they work with the body’s systems to potentially restore natural testosterone production while minimizing the risks of infertility and dependence on external testosterone. These drugs act on the hypothalamus and pituitary gland to increase the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones, in turn, stimulate the testes to produce more testosterone.